CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE
Cumberland Pharmaceuticals (NASDAQ: CPIX) announced it will release its Q2 2025 financial results and company update after market close on Tuesday, August 5, 2025, followed by a conference call at 4:30 p.m. Eastern Time.
The company, focused on specialty pharmaceuticals, maintains a portfolio of six FDA-approved products targeting hospital acute care, gastroenterology, and oncology segments. Additionally, Cumberland has ongoing Phase II clinical programs evaluating ifetroban for three conditions: Systemic Sclerosis, Duchenne Muscular Dystrophy-associated cardiomyopathy, and Idiopathic Pulmonary Fibrosis.
Cumberland Pharmaceuticals (NASDAQ: CPIX) ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre 2025 e un aggiornamento aziendale dopo la chiusura del mercato di martedì 5 agosto 2025, seguito da una conference call alle 16:30 ora della costa orientale.
L'azienda, specializzata in farmaci di nicchia, dispone di un portafoglio di sei prodotti approvati dalla FDA rivolti ai settori dell'assistenza acuta ospedaliera, gastroenterologia e oncologia. Inoltre, Cumberland sta conducendo programmi clinici di Fase II per valutare l'ifetroban in tre condizioni: sclerosi sistemica, cardiomiopatia associata alla distrofia muscolare di Duchenne e fibrosi polmonare idiopatica.
Cumberland Pharmaceuticals (NASDAQ: CPIX) anunció que publicará sus resultados financieros del segundo trimestre de 2025 y una actualización de la empresa después del cierre del mercado el martes 5 de agosto de 2025, seguido de una llamada telefónica a las 4:30 p.m., hora del Este.
La compañía, enfocada en productos farmacéuticos especializados, mantiene un portafolio de seis productos aprobados por la FDA dirigidos a los segmentos de atención aguda hospitalaria, gastroenterología y oncología. Además, Cumberland tiene en curso programas clínicos de Fase II que evalúan el ifetroban para tres condiciones: esclerosis sistémica, miocardiopatía asociada a la distrofia muscular de Duchenne y fibrosis pulmonar idiopática.
Cumberland Pharmaceuticals (NASDAQ: CPIX)는 2025년 2분기 재무 실적과 회사 업데이트를 2025년 8월 5일 화요일 장 마감 후 발표하며, 이어서 동부 표준시 기준 오후 4시 30분에 컨퍼런스 콜을 진행할 예정입니다.
특수 의약품에 주력하는 이 회사는 병원 급성 치료, 위장병학, 종양학 분야를 타겟으로 하는 FDA 승인 제품 6종을 보유하고 있습니다. 또한, Cumberland는 전신 경화증, 뒤쉔 근이영양증 관련 심근병증, 특발성 폐섬유증 등 세 가지 질환에 대해 이페트로반을 평가하는 2상 임상 프로그램을 진행 중입니다.
Cumberland Pharmaceuticals (NASDAQ: CPIX) a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2025 et une mise à jour de l'entreprise après la clôture des marchés le mardi 5 août 2025, suivis d'une conférence téléphonique à 16h30, heure de l'Est.
L'entreprise, spécialisée dans les produits pharmaceutiques de niche, possède un portefeuille de six produits approuvés par la FDA ciblant les segments des soins aigus hospitaliers, de la gastro-entérologie et de l'oncologie. De plus, Cumberland mène des programmes cliniques de phase II évaluant l'ifétroban pour trois pathologies : la sclérodermie systémique, la cardiomyopathie associée à la dystrophie musculaire de Duchenne et la fibrose pulmonaire idiopathique.
Cumberland Pharmaceuticals (NASDAQ: CPIX) gab bekannt, dass es seine Finanzergebnisse für das zweite Quartal 2025 und ein Unternehmensupdate nach Börsenschluss am Dienstag, den 5. August 2025 veröffentlichen wird, gefolgt von einer Telefonkonferenz um 16:30 Uhr Eastern Time.
Das Unternehmen, das sich auf Spezialpharmazeutika konzentriert, verfügt über ein Portfolio von sechs von der FDA zugelassenen Produkten, die auf die Bereiche Akutversorgung im Krankenhaus, Gastroenterologie und Onkologie abzielen. Darüber hinaus führt Cumberland laufende Phase-II-Studien durch, in denen Ifetroban für drei Erkrankungen untersucht wird: Systemische Sklerose, Duchenne-Muskeldystrophie-assoziierte Kardiomyopathie und idiopathische pulmonale Fibrose.
- None.
- None.
A conference call will be held on August 5 at 4:30 p.m. Eastern Time to discuss the results and update.
The link to register is: https://register-conf.media-server.com/register/BI0e0cfee6a381408fa7d3d939d82dfa04.
Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.
A replay of the call will be available for one year and can be accessed via the Investor Relations page of Cumberland's website or by visiting https://edge.media-server.com/mmc/p/zpxz72fn.
Cumberland Pharmaceuticals is a specialty pharmaceutical company dedicated to providing unique products that improve patient care. The Company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.
The company's portfolio of FDA-approved brands includes:
- Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) injection, for the treatment of pain and fever;
- Kristalose® (lactulose) for oral solution, a prescription laxative, for the treatment of constipation;
- Sancuso® (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
- Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
- Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
The Company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis, the cardiomyopathy associated with Duchenne Muscular Dystrophy and Idiopathic Pulmonary Fibrosis.
For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, found on the company's website at www.cumberlandpharma.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-q2-2025-financial-results--company-update-302516454.html
SOURCE Cumberland Pharmaceuticals Inc.
FAQ
When will Cumberland Pharmaceuticals (CPIX) release Q2 2025 earnings?
How can investors access Cumberland Pharmaceuticals' Q2 2025 earnings call?
What FDA-approved products does Cumberland Pharmaceuticals (CPIX) currently have?
What clinical trials is Cumberland Pharmaceuticals currently conducting?
